Aclarion, Inc., a healthcare technology company, has filed a prospectus with the SEC detailing the offer and resale of up to 27,515,153 shares of common stock. This includes up to 21,830,104 shares issuable upon conversion of Series C Convertible Preferred Stock and up to 5,685,049 shares issuable upon exercise of warrants, both resulting from a private investment in public equity (PIPE) financing under a Securities Purchase Agreement dated September 30, 2024. Aclarion is not selling any securities under this prospectus and will not receive proceeds from the sale of shares by the Selling Stockholders. However, the company may receive approximately $1.2 million from the cash exercise of the Common Warrants. The shares are to be sold by Selling Stockholders from time to time, at market prices...Show More

Aclarion, Inc., a healthcare technology company, has filed a prospectus with the SEC detailing the offer and resale of up to 27,515,153 shares of common stock. This includes up to 21,830,104 shares issuable upon conversion of Series C Convertible Preferred Stock and up to 5,685,049 shares issuable upon exercise of warrants, both resulting from a private investment in public equity (PIPE) financing under a Securities Purchase Agreement dated September 30, 2024. Aclarion is not selling any securities under this prospectus and will not receive proceeds from the sale of shares by the Selling Stockholders. However, the company may receive approximately $1.2 million from the cash exercise of the Common Warrants. The shares are to be sold by Selling Stockholders from time to time, at market prices or in negotiated transactions. Aclarion's common stock is listed on the Nasdaq Capital Market under the symbol 'ACON.' The company has received deficiency letters from Nasdaq for not complying with the minimum bid price and stockholders' equity requirements and is subject to potential delisting. Aclarion plans to implement a reverse stock split to regain compliance. The company has appealed the delisting notices and has been granted an extension until January 31, 2025, to demonstrate compliance.